JP MORGAN/CALL/ELI LILLY & CO/640/0.1/17.01.25 | Market Closed - Börse Stuttgart 04:35:09 2024-06-14 EDT | ||
| 25.62 EUR | +7.11% |
|
| Current month | +28.04% | ||
| 1 month | +68.11% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
| Date | Price | Change |
|---|---|---|
| 24-06-14 | 25.62 | +7.11% |
| 24-06-13 | 23.92 | -1.03% |
| 24-06-12 | 24.17 | -5.99% |
| 24-06-11 | 25.71 | +11.69% |
| 24-06-10 | 23.02 | +7.47% |
Delayed Quote Börse Stuttgart
Last update June 14, 2024 at 04:35 am
More quotesStatic data
| Product type | Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | J.P. Morgan |
| WKN | JL539C |
| ISIN | DE000JL539C0 |
| Date issued | 2023-06-29 |
| Strike | 640 $ |
| Maturity | 2025-01-17 (215 Days) |
| Parity | 10 : 1 |
| Emission price | 1.82 € |
| Emission volume | N/A |
| Settlement | règlement en espèces |
| Currency | EUR |
Technical Indicators
| Highest since issue | 25.71 € |
|---|---|
| Lowest since issue | 1.46 € |
| Delta | 0x |
| Omega | 0.000000 |
| Premium | 0x |
| Gearing | 0x |
| Moneyness | 1.373 |
| Difference Strike | -238.5 $ |
| Difference Strike % | -37.26% |
| Intrinsic value | 22.27 |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
878.4
USD
Average target price
855.4
USD
Spread / Average Target
-2.63%
- Stock Market
- Warrants
- Warrant
